⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 1985Journal of Clinical Oncology

Homoharringtonine as a new antileukemic agent.

Tomokazu Ohnuma J F Holland

View at Publisher

Ask AI

Bookmark

Share

Abstract

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.5.604 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3889228 Homoharringtonine as a new antileukemic agent. T OhnumaxT OhnumaSearch for articles by this author , J F HollandxJ F HollandSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.5.604 First Page PDF © 1985 by American Society of Clinical Oncology

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ohnuma et al. (1985) studied this question.

synapsesocial.com/papers/6a9c2edf332d6b9421cc67af https://doi.org/10.1200/jco.1985.3.5.604

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical TrialJournal of Clinical Oncology · 2026
2Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
3KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
4Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026
5Art as a Shared Space: Tracing the Unseen Through a Body MapJournal of Clinical Oncology · 2026

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0Journal of Clinical Oncology · 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 TrialJournal of Clinical Oncology · 2026
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract CancerJournal of Clinical Oncology · 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final AnalysisJournal of Clinical Oncology · 2026
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate CancerJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology